Early Lung Cancer Test Launch into NHS

Immunodiagnostics group Oncimmune Holdings plc is to supply its EarlyCDT Lung blood test to NHS Norfolk & Waveney Clinical Commissioning Group. Under this commercial contract, Norfolk & Waveney will be evaluating the use of the blood test in a clinical setting. A successful conclusion to this contract, combined with Guidance from NICE, is anticipated to support the adoption of this test into the clinical pathway for the early detection of lung cancer across NHS East of England.

The company is also supplying EarlyCDT Lung blood test into the NHS Lung Health Check Programmes in Wessex and Yorkshire as part of the iDx-LUNG evaluation programme. This will involve collection of blood samples from 15,000 people to be delivered through mobile CT scanning sites across Wessex and Yorkshire. As well as targeting increased survival rates, an aim of the iDx-LUNG programme is to streamline the process of detecting incident lung cancers in the community and so reduce the NHS resource needed to find each new lung cancer case.

 Additionally the company has been notified that The National Institute for Health and Care Excellence (NICE) has selected the EarlyCDT Lung blood test for Diagnostics Assessment Guidance.